Jump to content

Oleclumab: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Chembox edits: Set CSID to none
Line 41: Line 41:
| UNII = 5CRY01URYQ
| UNII = 5CRY01URYQ
| synonyms = MEDI9447
| synonyms = MEDI9447
| ChemSpiderID = none
}}
}}


Revision as of 12:42, 17 April 2018

Oleclumab
Monoclonal antibody
Type?
SourceHuman
Target5'-nucleotidase
Clinical data
Other namesMEDI9447
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6348H9826N1710O1998S40
Molar mass143.35 g/mol g·mol−1

Oleclumab (INN[1]) (MEDI9447) is a human monoclonal antibody designed for the treatment of pancreatic and colorectal cancer.

This drug was developed by MedImmune/AstraZeneca.[2]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oleclumab&oldid=836884175"